Literature DB >> 21647737

iScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan.

Tsung-Ying Tsai1, Kai-Wei Chang, Calvin Yu-Chian Chen.   

Abstract

The rapidly advancing researches on traditional Chinese medicine (TCM) have greatly intrigued pharmaceutical industries worldwide. To take initiative in the next generation of drug development, we constructed a cloud-computing system for TCM intelligent screening system (iScreen) based on TCM Database@Taiwan. iScreen is compacted web server for TCM docking and followed by customized de novo drug design. We further implemented a protein preparation tool that both extract protein of interest from a raw input file and estimate the size of ligand bind site. In addition, iScreen is designed in user-friendly graphic interface for users who have less experience with the command line systems. For customized docking, multiple docking services, including standard, in-water, pH environment, and flexible docking modes are implemented. Users can download first 200 TCM compounds of best docking results. For TCM de novo drug design, iScreen provides multiple molecular descriptors for a user's interest. iScreen is the world's first web server that employs world's largest TCM database for virtual screening and de novo drug design. We believe our web server can lead TCM research to a new era of drug development. The TCM docking and screening server is available at http://iScreen.cmu.edu.tw/.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21647737     DOI: 10.1007/s10822-011-9438-9

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  25 in total

1.  SYNOPSIS: SYNthesize and OPtimize System in Silico.

Authors:  H Maarten Vinkers; Marc R de Jonge; Frederik F D Daeyaert; Jan Heeres; Lucien M H Koymans; Joop H van Lenthe; Paul J Lewi; Henk Timmerman; Koen Van Aken; Paul A J Janssen
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

2.  A graph-based genetic algorithm and its application to the multiobjective evolution of median molecules.

Authors:  Nathan Brown; Ben McKay; François Gilardoni; Johann Gasteiger
Journal:  J Chem Inf Comput Sci       Date:  2004 May-Jun

3.  LEA3D: a computer-aided ligand design for structure-based drug design.

Authors:  Dominique Douguet; Hélène Munier-Lehmann; Gilles Labesse; Sylvie Pochet
Journal:  J Med Chem       Date:  2005-04-07       Impact factor: 7.446

4.  CONCERTS: dynamic connection of fragments as an approach to de novo ligand design.

Authors:  D A Pearlman; M A Murcko
Journal:  J Med Chem       Date:  1996-04-12       Impact factor: 7.446

5.  Automated site-directed drug design: the prediction and observation of ligand point positions at hydrogen-bonding regions on protein surfaces.

Authors:  D J Danziger; P M Dean
Journal:  Proc R Soc Lond B Biol Sci       Date:  1989-03-22

6.  BUILDER v.2: improving the chemistry of a de novo design strategy.

Authors:  D C Roe; I D Kuntz
Journal:  J Comput Aided Mol Des       Date:  1995-06       Impact factor: 3.686

7.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation.

Authors:  G Jones; P Willett; R C Glen
Journal:  J Mol Biol       Date:  1995-01-06       Impact factor: 5.469

8.  Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database.

Authors:  Calvin Yu-Chian Chen
Journal:  J Biomol Struct Dyn       Date:  2010-04

9.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach.

Authors:  Xiaofeng Liu; Sisheng Ouyang; Biao Yu; Yabo Liu; Kai Huang; Jiayu Gong; Siyuan Zheng; Zhihua Li; Honglin Li; Hualiang Jiang
Journal:  Nucleic Acids Res       Date:  2010-04-29       Impact factor: 16.971

10.  3DLigandSite: predicting ligand-binding sites using similar structures.

Authors:  Mark N Wass; Lawrence A Kelley; Michael J E Sternberg
Journal:  Nucleic Acids Res       Date:  2010-05-31       Impact factor: 16.971

View more
  51 in total

Review 1.  The re-emergence of natural products for drug discovery in the genomics era.

Authors:  Alan L Harvey; RuAngelie Edrada-Ebel; Ronald J Quinn
Journal:  Nat Rev Drug Discov       Date:  2015-01-23       Impact factor: 84.694

Review 2.  Shifting from the single to the multitarget paradigm in drug discovery.

Authors:  José L Medina-Franco; Marc A Giulianotti; Gregory S Welmaker; Richard A Houghten
Journal:  Drug Discov Today       Date:  2013-01-20       Impact factor: 7.851

3.  ACFIS: a web server for fragment-based drug discovery.

Authors:  Ge-Fei Hao; Wen Jiang; Yuan-Nong Ye; Feng-Xu Wu; Xiao-Lei Zhu; Feng-Biao Guo; Guang-Fu Yang
Journal:  Nucleic Acids Res       Date:  2016-05-05       Impact factor: 16.971

4.  Identification of new potent inhibitors of dengue virus NS3 protease from traditional Chinese medicine database.

Authors:  Vivek Dhar Dwivedi; Indra Prasad Tripathi; Shiv Bharadwaj; Aman Chandra Kaushik; Sarad Kumar Mishra
Journal:  Virusdisease       Date:  2016-07-20

5.  Residue-based design of small molecule inhibitor for H1N1, H5N1 and H7N1 mutants.

Authors:  Weng Ieong Tou; Kun-Lung Chang; Tung-Ti Chang; Cheng-Chun Lee; Calvin Yu-Chian Chen
Journal:  J Mol Model       Date:  2015-12-08       Impact factor: 1.810

Review 6.  Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications.

Authors:  Yuemin Bian; Xiang-Qun Sean Xie
Journal:  AAPS J       Date:  2018-04-09       Impact factor: 4.009

7.  In silico identification of potent pancreatic triacylglycerol lipase inhibitors from traditional Chinese medicine.

Authors:  Kuan-Yu Chen; Su-Sen Chang; Calvin Yu-Chian Chen
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

8.  In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.

Authors:  Weng Ieong Tou; Calvin Yu-Chian Chen
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

9.  A novel artificial intelligence protocol to investigate potential leads for Parkinson's disease.

Authors:  Zhi-Dong Chen; Lu Zhao; Hsin-Yi Chen; Jia-Ning Gong; Xu Chen; Calvin Yu-Chian Chen
Journal:  RSC Adv       Date:  2020-06-16       Impact factor: 4.036

10.  Virtual screening for oseltamivir-resistant a (H5N1) influenza neuraminidase from traditional Chinese medicine database: a combined molecular docking with molecular dynamics approach.

Authors:  Vasudevan Karthick; Karuppasamy Ramanathan
Journal:  Springerplus       Date:  2013-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.